Key Points
- CEO Jack Khattar sold 35,000 shares on March 13 at an average price of $50.37 for a total of $1,762,950, trimming his stake by 3.52% to 958,100 shares (≈$48.26M).
- Analyst coverage is mixed—four Buys, one Hold and two Sells—resulting in an average rating of Hold and a consensus target price of $62.17.
- Several institutions meaningfully increased positions—Woodline (+490,835 shares), Morgan Stanley (+324,154), Bank of America (+338,584) and UBS (+312,775)—and Rubric opened a new ~$21.9M position, signaling continued institutional interest.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Frederick Hudson sold 5,369 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the transaction, the director owned 60,413 shares of the company's stock, valued at $3,057,501.93. This trade represents a 8.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Supernus Pharmaceuticals Stock Up 0.6%
SUPN stock opened at $50.21 on Tuesday. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $59.68. The stock's fifty day simple moving average is $51.23 and its 200-day simple moving average is $49.13. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -73.84, a price-to-earnings-growth ratio of 1.55 and a beta of 0.70.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on SUPN. Zacks Research lowered Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Thursday, January 29th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Sunday, March 8th. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Stifel Nicolaus upped their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a "hold" rating in a research report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $62.17.
View Our Latest Report on Supernus Pharmaceuticals
Hedge Funds Weigh In On Supernus Pharmaceuticals
A number of large investors have recently modified their holdings of the company. Hantz Financial Services Inc. lifted its stake in shares of Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 281 shares in the last quarter. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth about $49,000. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals during the 3rd quarter worth approximately $50,000. EverSource Wealth Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000. Finally, Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 268 shares during the period.
Supernus Pharmaceuticals Company Profile
(
Get Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
